Free Trial
NASDAQ:XBIT

XBiotech (XBIT) Stock Price, News & Analysis

XBiotech logo
$2.84 0.00 (0.00%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.86 +0.02 (+0.53%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About XBiotech Stock (NASDAQ:XBIT)

Key Stats

Today's Range
$2.81
$2.96
50-Day Range
$2.77
$3.48
52-Week Range
$2.65
$8.64
Volume
39,527 shs
Average Volume
75,618 shs
Market Capitalization
$86.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

XBiotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
8th Percentile Overall Score

XBIT MarketRank™: 

XBiotech scored higher than 8% of companies evaluated by MarketBeat, and ranked 896th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for XBiotech.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of XBiotech is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of XBiotech is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    XBiotech has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about XBiotech's valuation and earnings.
  • Percentage of Shares Shorted

    4.61% of the float of XBiotech has been sold short.
  • Short Interest Ratio / Days to Cover

    XBiotech has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in XBiotech has recently increased by 28.81%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    XBiotech does not currently pay a dividend.

  • Dividend Growth

    XBiotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.61% of the float of XBiotech has been sold short.
  • Short Interest Ratio / Days to Cover

    XBiotech has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in XBiotech has recently increased by 28.81%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    XBiotech has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, XBiotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    33.10% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about XBiotech's insider trading history.
Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Stock News Headlines

Memorial Day Sale! 82% Off Disruptors and Dominators!
Jensen Huang recently gave the keynote speech at the Consumer Electronics Show in Las Vegas. When the Nvidia CEO walked on stage, you could've heard a pin drop. Why? Robots — built by Nvidia.
See More Headlines

XBIT Stock Analysis - Frequently Asked Questions

XBiotech's stock was trading at $3.95 at the beginning of 2025. Since then, XBIT shares have decreased by 28.1% and is now trading at $2.84.
View the best growth stocks for 2025 here
.

XBiotech Inc. (NASDAQ:XBIT) issued its quarterly earnings data on Wednesday, May, 14th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter.

XBiotech (XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

Top institutional shareholders of XBiotech include American Century Companies Inc. (0.33%), Charles Schwab Investment Management Inc. (0.22%), Connor Clark & Lunn Investment Management Ltd. (0.21%) and Goldman Sachs Group Inc. (0.15%).
View institutional ownership trends
.

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that XBiotech investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AUO (AUOTY).

Company Calendar

Last Earnings
5/14/2025
Today
5/24/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XBIT
Employees
100
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.01 million
Price / Cash Flow
N/A
Book Value
$7.19 per share
Price / Book
0.39

Miscellaneous

Free Float
20,393,000
Market Cap
$86.59 million
Optionable
Optionable
Beta
0.98

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:XBIT) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners